Skip to main content Accessibility help
×
Home

Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013

  • O. MOR (a1), I. OFIR (a1) (a2), R. PAVEL (a1), R. BASSAL (a3), Z. KRA-OZ (a4), D. COHEN (a2), T. SHOHAT (a2) (a3) and E. MENDELSON (a1) (a2)...

Summary

Differences in the seroprevalence and unique pattern of parvovirus B19 (B19V) acute infections have been documented around the world. This study was conducted to estimate the seroprevalence of anti-parvovirus B19V IgG antibodies in the Israeli population and to assess the pattern of acute infection based on data from two laboratories in Israel. The overall IgG prevalence in the 1008 representative sera samples was 61·4% and the age-adjusted prevalence rate was 58·2%. Seropositivity was significantly associated with age, ranging from 25·7% in children aged <10 years to 70% in people aged >20 years. While no significant differences in seropositivity were detected between sexes and population groups, significantly lower seroprevalence was observed in older Jews born in Africa or Asia. Acute infection rates of 4·1% (234 cases) were found based on the positive IgM results identified in samples from 5663 individuals collected between 2008 and 2013. Annual peaks of infection were observed in 2008 and 2011–2012 and major seasonal peak of B19V IgM positivity was identified in June each year. The number of requests for B19V serology was significantly higher for women aged 20–39 years while the majority IgM-positive cases were identified in young children. With more than 30% of the adult population being susceptible to B19V infection, monitoring B19V status should be considered in specific risk groups such as pregnant women.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013
      Available formats
      ×

Copyright

Corresponding author

* Author for correspondence: Dr O. Mor, Director, National HIV Reference Laboratory, Head, Laboratory of Clinical Virology, Ministry of Health, Sheba Medical Center, Ramat-Gan, Israel. (Email: orna.mor@sheba.health.gov.il)

References

Hide All
1. Juhl, D, Gorg, S, Hennig, H. Persistence of Parvovirus B19 (B19V) DNA and humoral immune response in B19V-infected blood donors. Vox Sanguinis 2014; 107: 226232.
2. Kumar, S, et al. Seroprevalence of human parvovirus B19 in healthy blood donors. Medical Journal, Armed Forces India 2013; 69: 268272.
3. Heegaard, ED, Brown, KE. Human parvovirus B19. Clinical Microbiology Reviews 2002; 15: 485505.
4. de Jong, EP, et al. Parvovirus B19 infection in pregnancy: new insights and management. Prenatal Diagnosis 2011; 31: 419425.
5. Bihari, C, et al. Parvovirus b19 associated hepatitis. Hepatitis Research and Treatment 2013; 2013: 472027.
6. Barah, F, et al. Neurological aspects of human parvovirus B19 infection: a systematic review. Reviews in Medical Virology 2014; 24: 154168.
7. Bock, CT, Klingel, K, Kandolf, R. Human parvovirus B19-associated myocarditis. New England Journal of Medicine 2010; 362: 12481249.
8. Kelly, HA, et al. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiology and Infection 2000; 124: 449457.
9. Reinheimer, C, et al. Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors. Infection 2010; 38: 381385.
10. Rohrer, C, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiology and Infection 2008; 136: 15641575.
11. van Rijckevorsel, GG, et al. Population-based study on the seroprevalence of parvovirus B19 in Amsterdam. Journal of Medical Virology 2009; 81: 13051309.
12. Matsunaga, Y, et al. Low prevalence of antibody to human parvovirus B19 in Singapore. Epidemiology and Infection 1994; 113: 537540.
13. Turk, Dagi H, et al. Investigation of parvovirus B19 seroprevalence in various age groups in Central Anatolia Region, Turkey [in Turkish]. Mikrobiyoloji Bulteni 2010; 44: 467472.
14. Letaief, M, et al. Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusional transmission. Transfusion Science 1997; 18: 523530.
15. Nicolay, N, Cotter, S. Clinical and epidemiological aspects of parvovirus B19 infections in Ireland, January 1996-June 2008. Eurosurveillance 2009; 14: 15.
16. Central Bureau of Statistics. Demographic review Israel 2011. (http://www1.cbs.gov.il/population/demo_skira.pdf). 2013. Accessed 2 January 2014.
17. Central Bureau of Statistics. Population, by population group, religion, sex and age. (http://www1.cbs.gov.il/shnaton64/st02_03.pdf). 2013. Accessed 15 August 2014.
18. Miron, D, et al. Age-related immunoglobulin G seroprevalence of human parvovirus B-19 in Israeli children. Israel Medical Association Journal 2010; 12: 277279.
19. Mossong, J, et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiology and Infection 2008; 136: 10591068.
20. CBS. House-hold by district, sub-district and population group. (http://www1.cbs.gov.il/publications12/1490/pdf/t02_04.pdf). 2009. Accessed 1 January 2014.
21. Ke, L, et al. The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Transfusion 2011; 51: 19091918.
22. Ziyaeyan, M, Rasouli, M, Alborzi, A. The seroprevalence of parvovirus B19 infection among to-be-married girls, pregnant women, and their neonates in Shiraz, Iran. Japanese Journal of Infectious Diseases 2005; 58: 9597.
23. Tolfvenstam, T, et al. Seroprevalence of viral childhood infections in Eritrea. Journal of Clinical Virology 2000; 16: 4954.
24. Metz, HC. Israel: A Country Study. Helen, CM, ed. Washington: GPO for the Library of Congress, 416 pp, 1988.
25. Enders, M, et al. Human parvovirus B19 infection during pregnancy – value of modern molecular and serological diagnostics. Journal of Clinical Virology 2006; 35: 400406.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed